Stocks Health care BCTX

NASDAQ · Health care

BriaCell Therapeutics Corp. (BCTX)

It posted a net loss of $30.7M. At April 30, 2026 it held $6.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on June 9, 2026.

What BriaCell Therapeutics Corp. does

BriaCell Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCTX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What BriaCell Therapeutics Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. June 26, 2026
   Investor disclosure 8-K
2. June 9, 2026
   Quarterly report 10-Q · period to April 30, 2026Diluted EPS -$0.99 versus -$16.42.
3. June 3, 2026
   Material agreement 8-K
4. June 2, 2026
   Securities offering prospectus 424B5
5. March 31, 2026
   Investor disclosure 8-K
6. March 10, 2026
   Quarterly report 10-Q · period to January 31, 2026Diluted EPS -$2.58 versus -$23.31.
7. March 9, 2026
   Shareholder vote results 8-K
8. February 26, 2026
   Delisting notice 25-NSE
9. February 20, 2026
   Other event 8-K
10. February 12, 2026
    Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 20, 2024. Insider transactions on SEC

Who owns BCTX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: CVI Investments, Inc. 4.9% (November 7, 2025); 3i, LP 4.9% (May 13, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BCTX

What does BriaCell Therapeutics Corp. do?

BriaCell Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCTX.

Is BriaCell Therapeutics Corp. profitable?

No. Over the twelve months to April 30, 2026 it reported a net loss of $30.7M.

When did BriaCell Therapeutics Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on June 9, 2026. It covers the period to April 30, 2026. Its newest filing of any kind is the investor disclosure from June 26, 2026.

Similar companies

Compare BCTX with

Compare BCTX with any company

Follow BCTX

Get an email when BriaCell Therapeutics Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BCTX: get an email when it files

Where the numbers come from

Financial figures are the values BriaCell Therapeutics Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.